DOK7 gene therapy enhances motor activity and life span in ALS model mice
Abstract Amyotrophic lateral sclerosis (ALS) is a progressive, multifactorial motor neurodegenerative disease with severe muscle atrophy. The glutamate release inhibitor riluzole is the only medication approved by the FDA, and prolongs patient life span by a few months, testifying to a strong need f...
Saved in:
| Main Authors: | Sadanori Miyoshi, Tohru Tezuka, Sumimasa Arimura, Taro Tomono, Takashi Okada, Yuji Yamanashi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2017-05-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201607298 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expression of amyotrophic lateral sclerosis associated protein disulfide isomerase A3 D217N variant recapitulates early morphological alterations at the neuromuscular junction
by: Martin Sepulveda, et al.
Published: (2025-10-01) -
Mechanisms of neuromuscular junction dysfunction in amyotrophic lateral sclerosis
by: Aydar N. Khabibrakhmanov, et al.
Published: (2025-04-01) -
Role of neuromuscular ultrasound in the evaluation of amyotrophic lateral sclerosis
by: Sherif Hassan Elwan, et al.
Published: (2025-03-01) -
Dysphagia and its impact on quality of life in rare neuromuscular disorders
by: Déborah Santos Sales, et al.
Published: (2025-02-01) -
Motor Neuron Disease: The Contribution of TAR-43 Gene in Amyotrophic Lateral Sclerosis
by: Gorky Guha
Published: (2023-08-01)